Treats Gastroesophageal Reflux Disease (GERD) with erosive esophagitis (EE). ANDA 204657, held by Eugia Pharma. Esomeprazole Sodium.
As of Nov 16, 2026, ANDA 204657 (Esomeprazole Sodium), held by Eugia Pharma, was first approved by FDA on Aug 10, 2016, with 7 approved supplements and 0 published complete response letters.
Esomeprazole sodium for injection is a proton pump inhibitor (PPI) indicated for the: Short-term treatment of Gastroesophageal Reflux Disease (GERD) with erosive esophagitis (EE) in adults and pediatric patients 1 month to 17 years of age, as an alternative to oral therapy when oral esomeprazole is not possible or appropriate. Risk reduction of rebleeding of gastric or duodenal ulcers following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers in adults. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 10, 2016 | Original application | Approved | None posted |
| Esomeprazole SodiumEQ 20MG BASE/VIAL · injectable;intravenous | Esomeprazole Sodium | Discontinued |
| Esomeprazole SodiumEQ 40MG BASE/VIAL · injectable;intravenous | Esomeprazole Sodium | Discontinued |
| Feb 23, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Feb 23, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Feb 23, 2024 | Supplement 4Labeling · Standard review | Approved | None posted |
| Feb 23, 2024 | Supplement 5Labeling · Standard review | Approved | None posted |
| Feb 23, 2024 | Supplement 6Labeling · Standard review | Approved | None posted |
| Feb 23, 2024 | Supplement 7Labeling · Standard review | Approved | None posted |
| Feb 23, 2024 | Supplement 8Labeling · Standard review | Approved | None posted |
| Aug 10, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters